Albert Labs

Imagine one treatment for mental health.

CSE: $ABRT

[Albert Labs @albertlabs]

💵 We have announced a private placement with 80% of our First In-Human trial funding arranged.

Funding:
👩‍🔬 In-Human trials
🇬🇧 MHRA Real-World Trial Application
🇺🇸 IND Filing (FDA)
💊 Implementation of Expanded Drug Discovery Pipeline
📈 OTC Quotation

https://t.co/RTZY2pa3M4

[Albert Labs @albertlabs]

Public and scientific interest in #psychedelic drugs has seen an exponential increase in recent years. Notable changes include the establishment of international psychedelic #research centres, considerable investment & innovation and regulatory changes.

[Albert Labs @albertlabs]

The push for #psilocybin is driven by its potential as a one-trip treatment for #mentalhealth issues, rather than long-term antidepressants.
Investors remain bullish on psychedelics, with a projected market size of $10.75bn by 2027.
https://t.co/GfR9QMJaK6
https://t.co/GfR9QMJaK6

[Albert Labs @albertlabs]

If you missed it watch our CEO and chairman Dr Michael Raymont answer some questions about #psilocybin and the growing body of evidence that suggests its efficacy as a treatment for #mentalhealth conditions.

https://t.co/iiCop6AsUb

[Albert Labs @albertlabs]

1 in 3 cancer patients suffer from depression and anxiety ❤️‍🩹

After 6-months of a Single-Dose of Psilocybin-therapy, 83% no longer suffer

Late-stage clinical trials in 2023 … but we need your support

Learn about our mission 👇

https://t.co/WftcFA2BRx

[Albert Labs @albertlabs]

A meta-analysis of five clinical trials suggests that psychedelic-assisted therapy can significantly reduce depression and anxiety symptoms in patients with advanced forms of cancer. We are commencing clinical trials on cancer-related distress.

https://t.co/6XOS3uyWFp

[Albert Labs @albertlabs]

3 million people in the United States have an #opioid use disorder, another 1.5 million people have dealt with methamphetamine misuse within the last year. 2 groundbreaking clinical trials are looking at the use of #psilocybin to address these issues.
https://t.co/ZjyMSFAVHR

[Albert Labs @albertlabs]

In a systematic review of randomized controlled trials in patients with life-threatening diseases, the potential impact of psychedelic drugs on #anxiety and #depression was assessed and showed promising outcomes versus placebo.

https://t.co/2DUkMd334F

[Albert Labs @albertlabs]

The highlights from our recent press release:

🗺️ We have announced the expansion of our drug pipeline.

💊 KRN-101 nears completion of its pre-clinical studies and initiation of Phase 1 clinical research.

🇵🇹 We have prepared an application for EU Grant Funding in Portugal.

[Albert Labs @albertlabs]

Psychedelic-assisted therapy may help reduce #depression & #anxiety symptoms in people with cancer. Research suggests that psychedelics might have an advantage over traditional prescription #antidepressants, helping patients deal with underlying #trauma.

https://t.co/bJ9S6dEZO4

[Albert Labs @albertlabs]

Imperial College London researchers used detailed brain imaging to study how DMT alters brain function. The drug caused increased connectivity across the brain, with more communication between different areas and systems.
https://t.co/iXuQVPv6fT

[Albert Labs @albertlabs]

A recent study published in @PNASNews has revealed the effects of #DMT, a powerful psychedelic found in #ayahuasca, on brain activity. The research showed that after the injection, brain networks broke down and overall connectivity increased.

https://t.co/XuqlpcajbY

[Albert Labs @albertlabs]

@Benzinga have summarised our latest press release on our recent IP progress. Have a look at their take if you missed the news: https://t.co/amsrRbSG3Z

[Albert Labs @albertlabs]

@Benzinga have summarised our latest press release on our recent IP progress. Have a look at their take if you missed the news: https://t.co/amsrRbS8er

[Albert Labs @albertlabs]

Exeter University in the UK is launching one of the world's first postgraduate qualifications on psychedelics, to equip healthcare workers and therapists with the knowledge necessary to use these drugs therapeutically.

https://t.co/1mL5yXQO4V

[Albert Labs @albertlabs]

💡 We have received preliminary acceptance of 35 novel inventive claims as part of our published International PCT Patent Application

Read our full press release here:

https://t.co/3r5dQbEw2X

[Albert Labs @albertlabs]

We are pleased to announce the expansion of an exciting drug pipeline, broadening our product portfolio and clinical strategy to additional key jurisdictions and licence indications.

Read our full press release below:

https://t.co/P0eZyFjCLX

[InvestingNewsNetwork @DigMedia]

As #psilocybin becomes a “breakthrough” #therapy for #mentalhealth, @albertlabs gears up for its first in-human study of KRN 101 drug from natural psilocybin mycelium for cancer-related #anxiety and #depression. #Psychedelics #Investing https://t.co/3gFT4oebMs

[Albert Labs @albertlabs]

Watch our CEO and chairman Dr Michael Raymont answer some questions about #psilocybin and the growing body of evidence that suggests its efficacy as a treatment for #mentalhealth conditions.

https://t.co/iiCop6AsUb

[Albert Labs @albertlabs]

Could psychedelic therapy represents a paradigm shift in mental #healthcare, incorporating both modern science and indigenous wisdom?
https://t.co/SldCxfdIwk